Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Jul 29.

Published in final edited form as: Cancer Res. 2009 Aug 25;69(17):6932–6940. doi: 10.1158/0008-5472.CAN-09-1682

Specific binding of [¹²³I]MIP-1072 (A) and [¹²³I]MIP-1095 (B) to PSMA in vivo. Radiolabeled compound (2 µCi/mouse at >1000 mCi/µmol) was injected alone (LNCaP tumor , PC3 tumor ) or co-injected with 50 mg/kg PMPA (LNCaP tumor , or PC3 tumor ) via the tail vein. Data are expressed as %ID/g.

Inline graphic — Specific binding of [¹²³I]MIP-1072 (A) and [¹²³I]MIP-1095 (B) to PSMA in vivo. Radiolabeled compound (2 µCi/mouse at >1000 mCi/µmol) was injected alone (LNCaP tumor , PC3 tumor ) or co-injected with 50 mg/kg PMPA (LNCaP tumor , or PC3 tumor ) via the tail vein. Data are expressed as %ID/g.